Browsing Tag
Roche
88 posts
Why amylin is gaining pharma attention in obesity drug development: From amycretin to AZD6234
Discover how Novo Nordisk, AstraZeneca, and others are betting on amylin-based obesity drugs like amycretin and AZD6234 to reshape metabolic care.
Genentech’s Lunsumio and Polivy combination triples remission in relapsed large B-cell lymphoma
Genentech's chemo-free Lunsumio and Polivy combo tripled remission time in relapsed B-cell lymphoma, signaling a shift toward outpatient oncology treatment.
The business of AI in oncology: Who’s building the platforms hospitals trust?
Tempus, Guardant, Freenome, and Paige are building the AI oncology platforms hospitals now rely on. Discover the financials and future shaping cancer diagnostics.
Why Alzheimer’s partnerships with Roche, BMS, and Novo Nordisk still matter for Prothena
Explore how Prothena’s strategic collaborations with Roche, BMS, and Novo Nordisk could shape the future of Alzheimer’s drug development.
PRX012 Alzheimer’s trial: Can Prothena rebound from birtamimab setback?
After a major clinical failure, Prothena shifts focus to Alzheimer’s drug PRX012. Will this next trial restore investor confidence?
Prothena halts birtamimab development after Phase 3 AFFIRM-AL trial fails to meet endpoints
Prothena ends birtamimab development after failed Phase 3 trial in AL amyloidosis. Find out how this impacts its pipeline, financials, and future direction.
Halozyme Therapeutics stock rises 6.27% after beating Q1 expectations, raising 2025 outlook
Halozyme Therapeutics stock rose as Q1 earnings beat expectations and 2025 guidance improved. See how ENHANZE® drives royalty growth and future prospects.
Roche bets big on America: $50bn to fuel next-gen weight loss drugs and diagnostics boom
Discover how Roche’s $50 billion U.S. investment is transforming pharma R&D, diagnostics, and job creation across eight states and reshaping global exports.
Roche partners with Zealand Pharma to advance petrelintide in obesity treatment
Roche has entered into an exclusive collaboration and licensing agreement with Zealand Pharma to develop and commercialise petrelintide…
Recursion Pharmaceuticals’ stock plunges 7% after shock Q4 loss – What went wrong?
Recursion Pharmaceuticals, a clinical-stage biotechnology company leveraging artificial intelligence for drug discovery, reported a significantly wider loss for…